2-Methyl-6-(phenylethynyl) pyridine (MPEP) reverses maze learning and PSD-95 deficits in Fmr1 knock-out mice by RÃ©no M. Gandhi et al.
CELLULAR NEUROSCIENCE
ORIGINAL RESEARCH ARTICLE
published: 06 March 2014
doi: 10.3389/fncel.2014.00070
2-Methyl-6-(phenylethynyl) pyridine (MPEP) reverses maze
learning and PSD-95 deficits in Fmr1 knock-out mice
Réno M. Gandhi, Cary S. Kogan* and Claude Messier
School of Psychology, University of Ottawa, Ottawa, ON, Canada
Edited by:
Laurie Doering, McMaster University,
Canada
Reviewed by:
Mohamed Jaber, INSERM, University
of Poitiers, France
Robert Weissert, University of
Regensburg, Germany
*Correspondence:
Cary S. Kogan, School of Psychology,
University of Ottawa, Vanier Building,
136 Jean-Jacques-Lussier Pvt.,
Ottawa, ON K1N 6N5, Canada
e-mail: ckogan@uottawa.ca
Fragile X Syndrome (FXS) is caused by the lack of expression of the fragile X mental
retardation protein (FMRP), which results in intellectual disability and other debilitating
symptoms including impairment of visual-spatial functioning. FXS is the only single-gene
disorder that is highly co-morbid with autism spectrum disorder and can therefore provide
insight into its pathophysiology. Lack of FMRP results in altered group I metabotropic
glutamate receptor (mGluR) signaling, which is a target for putative treatments. The
Hebb-Williams (H-W) mazes are a set of increasingly complex spatial navigation problems
that depend on intact hippocampal and thus mGluR-5 functioning. In the present
investigation, we examined whether an antagonist of mGluR-5 would reverse previously
described behavioral deficits in fragile X mental retardation 1 knock-out (Fmr1 KO) mice.
Mice were trained on a subset of the H-W mazes and then treated with either 20
mg/kg of an mGluR-5 antagonist, 2-Methyl-6-(phenylethynyl) pyridine (MPEP; n = 11) or
an equivalent dose of saline (n = 11) prior to running test mazes. Latency and errors were
dependent variables recorded during the test phase. Immediately after completing each
test, marble-burying behavior was assessed, which confirmed that the drug treatment
was pharmacologically active during maze learning. Although latency was not statistically
different between the groups, MPEP treated Fmr1 KO mice made significantly fewer
errors on mazes deemed more difficult suggesting a reversal of the behavioral deficit.
MPEP treated mice were also less perseverative and impulsive when navigating mazes.
Furthermore, MPEP treatment reversed post-synaptic density-95 (PSD-95) protein deficits
in Fmr1 KO treated mice, whereas levels of a control protein (β-tubulin) remained
unchanged. These data further validate MPEP as a potentially beneficial treatment for
FXS. Our findings also suggest that adapted H-W mazes may be a useful tool to document
alterations in behavioral functioning following pharmacological intervention in FXS.
Keywords: fragile X syndrome, Hebb-Williams mazes, 2-methyl-6-(phenylethynyl) pyridine, post-synaptic density-
95, Western blot
INTRODUCTION
Fragile X Syndrome (FXS) is a neurodevelopmental disorder
that is caused by the loss of function mutation of the fragile
X mental retardation 1 (Fmr1) gene on the X chromosome
(reviewed in O’Donnell and Warren, 2002; Santoro et al., 2012;
Online Mendelian Inheritance in Man ® [OMIM] 309550) result-
ing in lack of fragile X mental retardation protein (FMRP)
expression (Fu et al., 1991; Pieretti et al., 1991). In turn, lack
of FMRP results in a number of symptoms including disorders
of intellectual development, attention deficit and hyperactivity,
anxiety, epilepsy, as well as particular physical features such
as an elongated face and macroorchidism (Hagerman, 1996;
Turner et al., 1996; O’Donnell and Warren, 2002; Hatton et al.,
2006; Sullivan et al., 2006; Scerif et al., 2007). Importantly,
a large proportion of individuals (25–47%) affected by FXS
display autistic behaviors or a co-morbid diagnosis of autism
(Kaufmann et al., 2004; Hatton et al., 2006), making FXS the
only clear genetically associated form of autism. Relevant to the
present investigation, FXS patients display poorer performances
as compared to developmentally matched participants on a num-
ber of different visual-spatial dependent tasks (Cornish et al.,
1998, 1999; Kogan et al., 2004, 2009; MacLeod et al., 2010; Van
der Molen et al., 2010).
In fragile X mental retardation 1 knock-out (Fmr1 KO) mice
an exaggerated form of mGluR mediated long-term depression
(LTD) has been documented in hippocampal neurons (Huber
et al., 2002) evidenced by elevated levels of “LTD” proteins at
basal states (Nosyreva and Huber, 2006; Osterweil et al., 2010)
and by the internalization of AMPA receptors (Snyder et al.,
2001). Following the identification of, and much research on,
LTD in Fmr1 KO mice, the prevailing opinion is that Fmrp,
which binds to approximately 4% of total brain mRNA (Brown
et al., 2001; Darnell et al., 2011), acts as a translational suppressor
of proteins in vivo, many of which are implicated in synaptic
plasticity (Bassell and Warren, 2008; Darnell et al., 2011; Bhakar
et al., 2012).
It has been hypothesized that in the absence of the translational
suppression functions of Fmrp, abnormally elongated spines
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develop and are responsible for some of the clinical manifestations
of FXS such as disorders of intellectual development and audio-
genic seizures (Bear et al., 2004; Krueger and Bear, 2011). Thus,
intervention with antagonists that selectively target mGluR-5 has
been promising in that these agents can mitigate signaling and
as a result correct some of the downstream effects that occur in
the absence of Fmrp. Consistent with group I mGluR-signaling as
mediating prolonged LTD in Fmr1 KO mice, one study employed
small interfering RNA (siRNA) specific to the Fmr1 gene sequence
to demonstrate that reductions of Fmrp in dendrites of hip-
pocampal neurons lead to an increase in the internalization of
the AMPAR subunit, GluR1 (Nakamoto et al., 2007). Treatment
with 2-methyl-6-phenylethynyl-pyridine (MPEP), an mGluR5-
antagonist, rescued the abnormal AMPAR trafficking, an effect
not found for NMDA receptors (NMDARs). In the absence of
Fmrp and following 20 days of in vitro culturing, neurons from
adult Fmr1 KO mice were classified as having excess filopodia
(spines with a long and thin appearance) relative to wild-type
cultured neurons that had a mushroom shaped appearance with
a large spine head (de Vrij et al., 2008). Treatment of Fmr1 KO
neurons with two different mGluR-5 antagonists (200 µM MPEP
and 300 µM fenobam) for 4 h rescued the protrusion phenotype,
restoring the spine/filopodia ratio in Fmr1 KO neurons to the lev-
els observed in wild-type neurons (de Vrij et al., 2008). Consistent
with this finding, other researchers have reversed hippocampal
spine elongations by using alternative mGluR-5 antagonists such
as Mavoglurant (AFQ056; Levenga et al., 2011). Regarding cor-
tical neurons, in one study, daily administration of 20 mg/kg of
MPEP over the course of a week ameliorated average spine length
and density in adult Fmr1 KO mice without producing significant
tolerance or toxicity effects (Su et al., 2011).
Arguably the strongest support for targeting mGluR- signaling
with antagonists comes from research studies that cross-bred
Fmr1 KO mice with Grm5 mutant mice that have a 50% reduction
of mGluR-5 expression (rather than a complete KO which would
negatively impact brain function and lead to death). This proce-
dure rescued several phenotypic aspects of the FXS mouse model.
In this regard, reduction of mGluR-5 expression in Fmr1 KO mice
significantly reduced hippocampal LTD, rescued the increased
density of long and thin spines, reduced the elevated basal protein
synthesis rates and finally, reduced audiogenic seizures (Dölen
et al., 2007).
Behaviorally, Fmr1 KO mice of the hybrid strain C57Bl/6J X
Friend Virus B NIH Jackson (FVB/NJ) displayed increased center
square entries and duration during open field testing indicative of
impulsivity and disinhibiton. Single intraperitoneal (i.p.) injec-
tion of either 10 or 30 mg/kg of MPEP rescued these deficits such
that open field performance 30 min after injection was statistically
indistinguishable from control mice (Yan et al., 2005).
Despite much progress with antagonism interventions, there
remains a need for reliable and valid means of assessing improve-
ment in patients receiving treatments, which are comparable
to those used in animal studies. Typically human FXS studies
attempting to assess progress in various cognitive domains have
produced inconsistent findings as a result of outcome measures
that are confounded by floor and ceiling effects (Berry-Kravis
et al., 2006). We previously showed that Hebb-Williams (H-W)
mazes are a viable visual-spatial assay for use with both FXS par-
ticipants and KO mice. Both populations exhibit similar behav-
ioral impairments (i.e., more errors than controls) (MacLeod
et al., 2010). More recently, we demonstrated that Fmrp intact
mice, but not Fmr1 KO mice, evidenced upregulations of post-
synaptic density-95 (PSD-95) following completion of the H-
W mazes (Gandhi et al., 2014). Given that PSD-95 has been
hypothesized as a key protein ostensibly involved in both AMPAR
regulation and dendritic spine structure (Keith and El-Husseini,
2008), our data suggests that PSD-95 is a good candidate protein
in order to examine the effects of antagonism treatment in Fmr1
KO mice.
Thus, for the present study, we hypothesized that MPEP
treatment of Fmr1 KO mice would result in reversal of the
previously described deficit (i.e., significantly fewer errors) on
the H-W mazes as well as a reversal of the PSD-95 protein deficit
relative to saline treated controls. We also report results from a
manipulation check (i.e., a marble burying assay) experiment that
confirms that the MPEP treatment remains active throughout
maze testing. Specifically, when MPEP is pharmacologically
active, marble burying (a repetitive behavior) is significantly
reduced without a corresponding decline in locomotor activity
(Thomas et al., 2012).
METHODS
ANIMALS
A total of 22, male, naïve Fmr1 knock-out (KO) mice with a
FVB background, bred from homozygote mating pairs that had
been backcrossed for 11 generations, were obtained from Jackson
Laboratories (FVB.129P2-Fmr1tm1Cgr/J; JAX Stock # 004624; Bar
Harbor, ME, USA). These mice do not carry the rd1 mutation
and consequently, do not develop retinal degeneration. The
FVB genetic background was chosen in view of the documented
modest visual-spatial abilities (Dobkin et al., 2000; Van Dam
et al., 2000).
Mice were shipped at 4 weeks of age and were approximately
12 weeks old when they began experimental procedures. Mice
were given 2 weeks to acclimate to the vivarium. During that time,
they were housed in groups of four in standard (27× 21× 14 cm)
polypropylene cages. All mice were kept on a 12 h light-dark cycle
(light 07:00–19:00 h) in a temperature controlled environment
(21◦C) and fed Rodent Chow (Harlan Global, Mississauga, ON,
Canada) and tap water. Eight days prior to testing, all mice
were housed in individual cages. Behavioral testing took place
during 08:00–15:00 h to reduce variability associated with diurnal
rhythms. To ensure high levels of motivation during the study,
mice were maintained at approximately 85–90% of their original
body weight and were fed a food ration approximately 30 min
after daily testing procedures ended. The ethics protocol was
approved by the University of Ottawa Animal Care Committee
(UOACC) and precautions were taken to minimize any pain or
discomfort according to the guidelines of the Canadian Council
on Animal Care (CCAC).
APPARATUS
The H-W test apparatus was constructed according to the spec-
ifications outlined by the developers, Rabinovitch and Rosvold
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(1951). Specifically, the maze was built using black opaque plex-
iglass and fitted with a translucent plexiglass cover top (Plastics
of Ottawa Ltd., Ottawa, ON, Canada). The apparatus consisted
of a large open area, square in shape (60 × 60 × 10 cm),
with diagonally opposing start and goal box areas (20 × 10 ×
10 cm). The start and goal box areas were equipped with sliding,
removable plexiglass doors to control entry and confinement,
covered by clear plexiglass lids. In the goal box, a recessed food
cup (2.5 cm diameter) was placed in the center and baited with a
20 mg of Rodent Chow, during the latter phases of the experiment.
The floor of the square open area was delineated by 36 equally
sized squares. The squares were used as markers for manually
placing barriers that defined different maze problems and error
zones (Rabinovitch and Rosvold, 1951). The barriers (10 cm high)
were constructed with black opaque plexiglass. Extra-maze cues
were minimized by placing the apparatus on a desk table (100 ×
75 cm) and by enclosing it within white wall coverings hanging
from the ceiling.
DRUG TREATMENT
Gq-coupled, group I metabotropic glutamate receptors (mGluR)
consist of two different types of receptors. Treatments for FXS
targeting mGluR-5 receptors have been favored over mGluR-1
receptors given that the latter produces motor deficits in animals
(Berry-Kravis et al., 2011). As such, the mGluR-5 antago-
nist, MPEP, MW 229.70, (MPEP; Sigma Aldrich, Oakville, ON,
Canada) was used in the current investigation. MPEP is a potent
and selective antagonist of mGluR-5 that is able to cross the
blood-brain barrier readily (Gasparini et al., 1999). Regarding
preparation, drug powder was dissolved into a vehicle (saline)
and aliquots containing 5mg/ml of stock solution were stored at
−20◦C. Thereafter single aliquots were allowed to warm to room
temperature, briefly centrifuged, and MPEP treated mice received
an intraperitoneal (i.p.) injection of 20 mg/kg based on their body
weight on the day of testing. Similarly, aged matched control mice
were administered an equivalent dose of saline without the drug
based on their body weight. MPEP was previously reported to be
biologically active from 15 to 75 min following i.p. injections (Yan
et al., 2005). Based on this data and to allow sufficient time for
the drug to take effect, mice in both groups were tested 30 min
following drug or vehicle-only administration. The mg/kg dosage
was determined based on a pilot study prior to experimentation
(see data below).
PILOT STUDY—DOSE RESPONSE DETERMINATION
Studies using Fmr1 KO mice and MPEP treatments (via an
i.p. route of administration) followed by behavioral testing have
attempted to optimize effective dose ranges from 0.05 mg/kg to
40 mg/kg (Yan et al., 2005; Su et al., 2011; Thomas et al., 2012).
Based on the results from these studies, an initial pilot study was
conducted with Fmr1 KO mice (N = 6; Jackson Laboratories,
Bar Harbor, ME, USA; FVB.129P2-Fmr1tm1Cgr/J; JAX Stock #
004624). Mice (n = 2) received vehicle, 20 mg/kg or 30 mg/kg
of MPEP treatments over consecutive 4 days. Vehicle or MPEP
treatments were administered twice per day (08:00 and 13:00 h)
and mice were allowed 30 min to allow sufficient time for the
drug to take effect prior to participating in the marble burying
assay. The total number of marbles buried collapsed across 4 days
and 8 marble burying trials was measured. Bonferroni adjusted
independent sample t-tests (α = 0.05/3 = 0.017) indicated there
was significantly less marbles buried by 20 mg/kg treated mice
relative to vehicle treated mice (t = 9.40, p = 0.011); and by 30
mg/kg treated mice relative to controls (t = 12.80, p = 0.006).
However, there were no differences in aggregated marbles buried
between the two doses of MPEP treatment (t = 0.949, p = 0.433).
As such, the dose used for MPEP treated mice in the current
investigation was set at 20 mg/kg to avoid potential unwanted side
effects from the higher dose.
MARBLE BURYING
A marble burying assay (Thomas et al., 2009) was used to ensure
that MPEP doses were biologically active before and after maze
testing. This assay reflects repetitive digging behavior without
habituation effects to burying even if marble presentations are
repeated multiple times during the same day or across several
days (Thomas et al., 2009). The number of marbles buried
decreases following the administration of Grp I mGluR antag-
onists (Thomas et al., 2012) and MPEP treatment does not
significantly reduce voluntary locomotor. Concerning the assay
itself, 20 marbles of varying color were arranged (15 mm in
diameter) in a 4 × 5 pattern on top of approximately three and a
half cm of bedding (SANI-CHIP) using clean (27 × 21 × 14 cm)
polypropylene cages. Approximately 4 cm of open space, clear of
marbles was left at one end of each cage in order to place a single
mouse into the apparatus. Each mouse was allotted 20 min to
bury as many marbles as possible. Marbles were considered buried
if they were covered by >50% of SANI-CHIP bedding.
PROCEDURE
All 22 Fmr1 KO mice underwent behavioral testing with half of
the animals (n = 11) receiving 20 mg/kg treatment of MPEP and
the others an equivalent dose of vehicle only (n = 11). The experi-
ment was conducted in three phases: habituation, acquisition and
testing. During the habituation phase, the H-W apparatus was
cleared of all barriers and each mouse was allowed 20 min/day
on 4 consecutive days to explore the maze including the start and
goal box areas. During the last 2 days, the goal box area was baited
with 20 mg of Rodent Chow and each mouse had ad lib access to
the food for the duration of the session.
The acquisition phase consisted of training mice on six practice
mazes (Figure 1A). Specifically, each mouse was trained for 2 ses-
sions per day, the first starting at 08:00 h and the second at 13:00 h.
Each session consisted of one of six possible practice mazes (five
trials per maze) commencing with maze A. A trial was considered
complete when the mouse entered the goal area and took a bite
of food or 180 s had elapsed. Mice completed all six acquisition
mazes in sequence (A–F) as many times as necessary for them
to reach criterion; that of 2 consecutive sessions completed in
less than 30 s each. The mean time to complete the acquisition
phase was 11.6 days. Mice that were assigned to either MPEP or
vehicle treatment during the subsequent phase (i.e., testing) did
not differ in the number of days required to reach criterion in the
acquisition phase (t = 0.18, p = 0.86).
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FIGURE 1 | Maze configurations. (A) Testing was conducted during the
acquisition phase using the six practice mazes labeled (A–F) and (B) the
seven test mazes depicted, each of which was used during the testing phase.
For each maze configuration, the (S) indicated in the bottom right hand corner
represents the start box, while the (F) in the top left corner represents the
goal box. Error zones are delineated by the dotted lines.
Following acquisition, mice were given a selection of the
standard test mazes (Figure 1B; Rabinovitch and Rosvold, 1951)
based on the same procedures used during acquisition. 30 min
prior to maze running mice were administered a either a dose
of 20 mg/kg of MPEP or an equivalent volume of vehicle. Mice
were then tested on a different maze in each session (five trials per
maze) in the same order (i.e., #2, #4, #5, #8, #9, #11, #12) until all
seven were completed, spanning 3.5 days/animal. The dependent
measures of interest were latency and number of errors. Latency
was recorded from the moment the barrier in the start box was
raised until the animal took its first bite of food. An error was
registered each time a mouse crossed its two front paws into a
defined error zone (Figure 1B). Data from the testing phase were
recorded using an overhead SONY camcorder and Media Cruise
software (Thomson Canopus Co. Ltd., Kobe, Japan) on a standard
desktop computer. Immediately after each maze, individual mice
were placed in separate marble burying assays for 20 min each,
following which the number of marbles buried was recorded.
Over all phases of the study, the experimenter was never visible
during the runs. To reduce odors from conspecifics, the maze was
thoroughly cleaned between trials with diluted ethanol.
WESTERN BLOT
Immediately after finishing the H-W mazes, mice were euthanized
(100 µl i.p. injection of euthasol; Sigma Aldrich, Oakville, ON,
Canada), their brains removed and tissue blocks were cut using
a stainless steel brain matrix (1 × 1.5 × 0.75 inches). Both
dorsal hippocampi were dissected according to a mouse atlas and
frozen on dry ice (Paxinos and Franklin, 2001). Western blots
were then prepared as described previously (Choeiri et al., 2006).
Briefly, hippocampi were homogenized over ice in a homogenate
buffer/protease inhibitor cocktail (Sigma Aldrich, Oakville, ON,
Canada). The homogenates were centrifuged, protein content
was quantified using a standard BSA kit (Pierce, Rockford, IL,
USA) and samples were frozen at −80◦C until further analysis.
Proteins were loaded at a concentration of 300 µg/ml and sam-
ples in quadruplicate (12 µg/lane) were resolved by SDS-PAGE.
Proteins were then transferred to pure nitrocellulose membranes
and blocked for 1 h in 5% skim milk and 10 M phosphate
buffered saline (PBS) solution at room temperature. Antibody
specificity was determined prior to commencing Western blot
analyses on experimental animals by confirming a single band of
binding of the protein of interest at the appropriate molecular
weight. Optimal concentrations of primary/secondary antibody
were then confirmed by serial dilutions. Membranes were incu-
bated in 5% skim milk and TBST (20 mM Tris/HCl, 137 mM
NaCl, 0.4% Tween 20, pH 7.6) solution with monoclonal anti-
PSD-95 antibody (1:2000; Millipore Corporation, Burlington,
ON, Canada) and monoclonal anti-β-tubulin antibody (1:10,000;
Sigma Aldrich, Oakville, ON, Canada) at 4◦C overnight. After 3
× 10 min washes in TBST, fluorescent Alexa 680-linked antibody
(1:10,000, Molecular Probes, Burlington, ON, Canada) and IR
800 antibody (1:10,000; LI-COR Biosciences, Lincoln, NE, USA)
in 5% skim milk and TBST solution were applied for 1 h at 4◦C.
After 3 × 10 min washes in TBST, Western blots were scanned
using the Odyssey infra-red system (LI-COR Biosciences, Lincoln,
NE, USA) in 700 and 800 nm channels in a single scan at 169 µm
resolution. Simultaneous detection of two fluorescent antibodies
(i.e., Alexa 680 and IR 800) allowed for the measurement of PSD-
95 and β-tubulin proteins within each sample. The density of each
protein band of interest was measured, background subtracted
and normalized to β-tubulin by the LI-COR analysis software.
STATISTICAL ANALYSES
Latency to complete the H-W mazes, number of errors, as well
as hippocampal PSD-95 levels in MPEP treated mice compared
with saline treated controls were the variables of interest in this
study. Using SPSS 19 (IBM Canada Ltd., Markham, Canada),
latency was analyzed by a 2 × 7 × 5 mixed-design ANOVA with
treatment (MPEP; saline) as the between-subjects variable and
both maze (seven levels) and trial (five levels) as the repeated
measures variables. Similarly, the number of errors made on the
H-W mazes was analyzed by a separate 2 × 7 × 5 mixed-design
ANOVA. Prior to analyses, data were evaluated to ensure that
assumptions underlying mixed-design ANOVA were met. These
preliminary analyses indicated that the majority of the latency as
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well as error data were skewed, and consequently, these variables
were subjected to log10 transformations in order to normalize the
distributions of the data. Following log10 transformation, neither
latency nor error data were identified as outliers (>four SDs from
the group mean; Van Selst and Jolicoeur, 1994). There were no
missing data in this study.
In order to confirm the effectiveness of MPEP treatment, each
mouse underwent the marble burying assay immediately after
each test maze. These data remained skewed following square
root, log10, and inverse transformations and therefore were not
amenable to a 2× 7 ANOVA analysis. As such, data were analyzed
using several non-parametric two independent sample, Mann-
Whitney U-tests. Specifically, analyses focused on the number of
marbles buried following completion of each maze as a function
of treatment (MPEP; saline). Assumptions underlying the Mann-
Whitney U-tests were met prior to running the analyses.
To examine protein levels following mGluR-5 antagonist
treatment, an independent samples t-test was performed with
treatment (MPEP; saline) as the independent variable and the
protein ratio of PSD-95 normalized to a control protein, β-
tubulin, as the dependent variable. To ensure equal loading of
protein samples across groups, an additional t-test was conducted
with treatment as the independent variable (MPEP; saline) and
β-tubulin as the dependent variable. Prior to analyses, data were
evaluated to ensure that assumptions underlying independent
samples t-test were met.
In order to examine the association between protein
expression and behavioral performance, three separate bivariate
correlations (Pearson’s r) were conducted. The correlational anal-
yses were based on relative PSD-95 protein levels (normalized to
β-tubulin) and mean total errors on the H-W mazes, defined as
aggregate errors divided by the total number of learning trials
(maze × trials = 35). Specific correlations focused on the rela-
tionship between PSD-95 protein levels and mean errors from:
(1) Fmr1 KO maze runners of both treatments; (2) MPEP treated
runners only; and (3) saline treated runners only. As a control,
correlations were also performed between β-tubulin protein levels
and mean total errors from #1.
Given the a priori hypotheses that specified the direction of the
effect in each of the aforementioned correlations, one-tailed tests
of significance for the correlational coefficients were conducted.
RESULTS
A 2 × 7 × 5 mixed measures ANOVA was conducted to evaluate
the effects of treatment (MPEP; saline) as the between-groups
measure and repeated measures of both maze (seven levels) and
trial (five levels) on the latency to complete the H-W mazes.
There was a main effect for maze, F(5,94) = 3.01, p = 0.01, partial
η2 = 0.13, and for trial, F(3,67) = 60.12, p < 0.001, partial η2 =
0.75, but not for treatment, F(1,20) = 1.45, p = 0.24, partial η2 =
0.07, indicating that the latency to complete the mazes did not
differ between MPEP and saline treated mice. There was also a
significant interaction between treatment and maze, F(5,94) = 4.06,
p = 0.003, partial η2 = 0.17, as well as maze and trial F(9,189) =
1.89, p = 0.05, partial η2 = 0.08. However, the interaction between
treatment and trial F(3,67) = 1.07, p = 0.37, partial η2 = 0.05
was not significant. Likewise, the three-way interaction between
FIGURE 2 | (A) Latency to complete each Hebb-Williams (H-W) test maze
for Fmr1 KO mice treated with saline or MPEP. Drug treatment did not
statistically affect completion times between groups. Error bars represent
the S.E.M. (B) Mean errors collapsed across trials for each H-W test maze
for Fmr1 KO mice treated with saline or MPEP. Mice treated with MPEP
made significantly fewer errors on mazes #8, 11 and 12. Error bars
represent the S.E.M; * p < 0.007.
treatment, maze, and trial was not significant F(9,189) = 1.01, p =
0.44, partial η2 = 0.05.
Bonferroni corrections were made to the α-level of 0.05 before
exploring simple main effect analyses of treatment within maze,
resulting in p < 0.007 (0.05/7 = 0.007) for significance. These
analyses indicated that there were differences in the latencies
between MPEP and saline treated mice on maze #9, F(1,20) = 5.08,
p = 0.04, partial η2 =0.20, maze #11, F(1,20) = 5.36, p = 0.03, partial
η2 = 0.21 and maze #12, F(1,20) = 6.08, p = 0.02, partial η2 =
0.23. However, given the adjustment to guard against Type I error,
these differences were deemed not statistically significant. Given
the similar latencies to complete maze running between drug
and vehicle groups, these findings are consistent with previous
research indicating that MPEP treatment does not significantly
reduce locomotor activity (Figure 2A).
Bonferroni corrections were made to the α-level of 0.05
before exploring simple main effect analyses of trial within maze,
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resulting in p < 0.007 (0.05/7 = 0.007) for significance. These
analyses indicated that there were differences in the latencies
between trials on maze #2, F(4,17) = 7.64, p = 0.001, partial
η2 =0.64, maze #4, F(4,17) = 23.36, p = 0.000001, partial η2 = 0.85,
maze #5, F(4,17) = 6.22, p = 0.003, partial η2 = 0.59, maze #8, F(4,17)
= 11.05, p = 0.0001, partial η2 =0.72, maze #9, F(4,17) = 11.26, p =
0.0001, partial η2 = 0.73, maze #11, F(4,17) = 12.54, p = 0.0001,
partial η2 = 0.75, but not on maze #12, F(4,17) = 4.68, p = 0.01,
partial η2 = 0.52.
Pairwise comparisons on the latency data adjusted to control
for the effects of comparing mean trial differences within each
maze (α = 0.05/60 = 0.0008) showed that on maze #2, Fmr1 KO
mice were significantly slower on trial 1 relative to completion
times on trials 3 and 4. In addition they were significantly slower
on trial 2 compared to trial 4. On maze #4, mice were slower on
trial 1 compared to their completion times on trials 3, 4 and 5;
whereas trial 2 took longer to complete than trial 4. On maze #5,
mice took longer to complete trial 1 compared with run times
on trials 4 and 5. Subsequently, mice completed maze #8 slower
on trial 1 compared to trials 2, 3, 4 and 5, whereas trial 4 was
completed faster than trial 2. During maze #9, latencies were again
slower on trial 1 compared with trials 3, 4 and 5. Finally on maze
#11, run times were quicker on trials 2, 3 and 5 relative to trial
1. Thus, despite some variability in the trial by maze interaction
data, pairwise comparisons indicated latencies were longest for
trial 1 and in general, tended to decrease with increased repetition,
as would be expected if mice were learning the maze configuration
and motivated to obtain the food reward.
Regarding error data, a 2 × 7 × 5 mixed measures ANOVA
was conducted to evaluate the effects of treatment (MPEP; saline)
as the between-groups measure and repeated measures of both
maze (seven levels) and trial (five levels) on the number of errors
committed on the H-W mazes. There was a main effect for
treatment F(1,20) = 63.71, p < 0.001, partial η2 =0.76, for maze,
F(4,84) = 4.13, p = 0.004, partial η2 = 0.17, indicating that the
number of errors made on the mazes differed between MPEP
and saline treated mice. There was also a main effect for trial,
F(3,65) = 24.43, p< 0.001, partial η2 = 0.55. There was a significant
interaction between treatment and maze, F(4,84) = 2.82, p = 0.03,
partial η2 = 0.12, whereas the interaction between treatment
and trial F(3,65) = 2.22, p = 0.09, partial η2 = 0.10 approached
significance. However, the interaction between maze and trial
F(9,188) = 1.32, p = 0.23, partial η2 = 0.06 was not significant.
Likewise, the three-way interaction between treatment, maze, and
trial was not significant F(9,188) = 0.94, p = 0.50, partial η2 = 0.04.
Bonferroni corrections were made to the α-level of 0.05 before
exploring simple main effect analyses of treatment within maze,
resulting in p < 0.007 (0.05/7 = 0.007) for significance. These
analyses indicated that there were significantly less errors com-
mitted by MPEP treated mice on maze #2, F(1,20) = 6.21, p = 0.02,
partial η2 = 0.24, maze #4, F(1,20) = 5.94, p = 0.02, partial η2 =
0.23, maze #8, F(1,20) = 8.67, p = 0.007, partial η2 = 0.30, maze #9,
F(1,20) = 7.53, p = 0.01, partial η2 = 0.27, maze #11, F(1,20) = 30.80,
p = 0.00002, partial η2 = 0.61, and maze #12, F(1,20) = 17.28, p =
0.0005, partial η2 = 0.46, However, when adjustments were made
to guard against Type I error, MPEP treated mice committed
significantly fewer errors on only three mazes relative to saline
FIGURE 3 | Mean errors on Hebb-Williams (H-W) test mazes for Fmr1
KO mice treated with saline or MPEP across trials. MPEP treated Fmr1
KO mice made significantly fewer errors on trials 1, 2, 4, and 5. Error bars
represent the S.E.M; * p < 0.005.
controls (mazes #8, 11, 12). Combined, these data indicate that
on several of the H-W mazes, MPEP administration results in
significantly less errors than in Fmr1 KO mice treated with saline
only (Figure 2B).
Bonferroni corrections were made to the α-level of 0.05 before
exploring simple main effect analyses of treatment within trial,
resulting in p < 0.01 (0.05/5 = 0.01) for significance. MPEP
administration resulted in significantly fewer errors on trial 1,
F(1,20) = 54.95, p = 0.0000004, partial η2 = 0.73, trial 2, F(1,20) =
17.16, p = 0.001, partial η2 = 0.46, trial 4, F(1,20) = 21.62, p =
0.0002, partial η2 = 0.52, and trial 5, F(1,20) = 25.97, p = 0.0001,
partial η2 = 0.57. Unexpectedly, treatment had no effect on the
mean errors observed on trial 3, F(1,20) = 4.43, p = 0.05, partial
η2 = 0.18. Thus, MPEP treatment reduces errors committed on
four out of five trials with the biggest impact (as reflected by effect
size) occurring on the first trial (Figure 3).
Several Mann-Whitney U-tests were conducted to evaluate
whether MPEP remained at physiologically active levels during
the experiments. Bonferroni corrections were made to the α-
level of 0.05 before performing these tests, resulting in p <
0.007 (0.05/7 = 0.007) for significance. The results of the Mann-
Whitney U-tests were in the expected direction and significant
such that MPEP treated mice were found to bury significantly
more marbles than saline treated controls for maze #2, z =−3.306,
p = 0.001 (MPEP average rank = 6.95; Saline = 16.95), maze #4,
z =−3.31, p = 0.001 (MPEP average rank = 6.95; Saline = 16.05),
maze #8, z =−3.30, p = 0.001 (MPEP average rank = 6.95; Saline =
16.05), maze #9, z =−2.74, p = 0.006 (MPEP average rank = 7.73;
Saline = 15.27), maze #11, z = −3.34, p = 0.001 (MPEP average
rank = 6.95; Saline = 16.05), and maze #12, z = −3.56, p < 0.001
(MPEP average rank = 6.59; Saline = 16.41). With the adjusted
level of α, the number of marbles buried was not statistically
different between MPEP and saline treated mice for maze #5, z =
−2.58, p = 0.01 (MPEP average rank = 7.95; Saline = 15.05). Taken
together, the marble burying assay following the completion of
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FIGURE 4 | Mean marbles buried across each Hebb-Williams (H-W) test
maze for Fmr1 KO mice treated with saline or MPEP. MPEP treated mice
buried significantly less marbles following each maze except for maze 5.
Data were analyzed by non-parametric, Bonferroni corrected Mann Whitney
U-tests; * p < 0.007.
each of the H-W test mazes confirmed that the MPEP treatment
was physiologically active during the test phases (Figure 4).
Independent sample t-tests were performed to evaluate the
hypothesis that mGluR-5 antagonist treatment could selectively
rescue hippocampal PSD-95 protein levels. Hippocampal β-
tubulin levels were also measured because this housekeeping
protein was not expected to vary with treatment condition.
Bonferroni corrections were made to the α-level of 0.05 before
performing these tests, resulting in p< 0.025 (α = 0.05/2 = 0.025)
for significance. The t-tests indicated that PSD-95 levels were
significantly higher in MPEP treated mice compared with vehicle
condition, t(20) = 3.00, p = 0.007, 95% CI [0.064, 3.56], whereas
there were no differences in β-tubulin levels between MPEP and
vehicle treated mice, t(20) = 0.851, p = 0.40, 95% CI [−0.80,
1.89]. The effect size as reflected by, η2, indicated that 31% of
the variance in PSD-95 levels was accounted for by whether or
not mice received MPEP/vehicle treatment whereas only 0.03% of
the variance in β-tubulin levels was accounted for the treatment.
These data suggest that mGluR-5 antagonism has an augmenting
affect on the levels of the scaffolding protein PSD-95 (Figure 5).
Similar to the group data from Gandhi et al. (2014; that
comprised the entire sample of animals) a correlation of all
Fmr1 KO mice, irrespective of treatment, indicated there was a
negative association between PSD-95 levels and mean total errors
on the H-W mazes, r(20) = −0.40, p = 0.03, r2 = 0.16 (Figure 6).
This association was not evident when examining the correlation
between β-tubulin levels and mean total errors from Fmr1 KO
mice, r(20) =−0.26, p = 0.12, r2 = 0.06. Within treatment groups,
there were no relationships between the PSD-95 levels of MPEP
treated mice and mean total errors, r(9) = −0.042, p = 0.45,
r2 = 0.01, nor saline treated mice and mean total errors, r(9) =
0.28, p = 0.21, r2 = 0.08. In addition, after adjusting the α-levels
FIGURE 5 | Representative Western blots from dorsal hippocampi of
Fmr1 KO mice treated with saline or MPEP for protein expression of
PSD-95 and β-tubulin. PSD-95 is found around the expected molecular
weight of 95 kDa and β-tubulin is found at 55 kDa. PSD-95 levels are
rescued in MPEP treated Fmr1 KO mice only. Error bars represent the
S.E.M; * p < 0.025.
to control for repeated tests, (0.05/4 = 0.012) only the initial cor-
relation consisting of the entire sample of Fmr1 KO mice trended
towards significance. Collectively, these data confirm that as PSD-
95 levels increase, mean errors on the H-W mazes decrease and
vice versa.
DISCUSSION
FXS is a debilitating mental, physical, and behavioral condition
that occurs due to lack of expression of the Fragile X Mental Retar-
dation 1 protein (FMRP; reviewed in Santoro et al., 2012). The
altered expression results in a number of characteristic symptoms
including disorders of intellectual development and frequently
co-morbid autism spectrum disorder. Visual-spatial impairment
is part of the cognitive profile in FXS and was the focus of the
present investigation. Despite a common finding in the research
literature that hippocampal lesions impair performance on tasks
of spatial navigation and learning (Morris et al., 1982; Sutherland
et al., 1982; Jarrard, 1993; Hock and Bunsey, 1998; Lee and Kesner,
2003; Clark et al., 2005; Okada and Okaichi, 2009), inconsistent
results have been reported when testing Fmr1 KO mice. These
differences may be a function of variability in the background
strain used or the assays employed. In the present study we
employed maze learning tasks, the H-W mazes, previously shown
to be sensitive to detecting dorsal hippocampal deficits (Shore
et al., 2001; Rogers and Kesner, 2006) including in a murine
model of FXS, Fmr1 KO mice. Concomitant with greater errors
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FIGURE 6 | Levels of hippocampal PSD-95 but not control protein
(β-tubulin) are correlated with behavioral performance. A negative
correlation between mean errors on the Hebb-Williams (H-W) mazes and
PSD-95 protein levels was observed, r (20) = −0.40, p = 0.03, r2 = 0.16. * p
< 0.05.
committed by Fmr1 KO as compared to wild type mice (MacLeod
et al., 2010), PSD-95, a hippocampal protein involved in synaptic
plasticity and a target of Fmrp, is selectively upregulated in wild
type but not KO mice (Gandhi et al., 2014). We demonstrate
here that a selective antagonist for mGluR-5, MPEP, reverses
both behavioral deficits in Fmr1 KO mice, as evidenced by fewer
errors in treated vs. saline treated animals on most H-W maze
problems, as well as the molecular deficit of interest, that is, PSD-
95 levels. These results provide support for the importance of
mGluR-5 signaling generally, and PSD-95, in particular, in the
pathophysiology of FXS and autism spectrum disorder.
Although the molecular mechanisms of synapse modifica-
tions at dendritic spines are unknown, one perspective is that
certain scaffolding proteins maintain the long-term transmission
efficiency of a synapse (Ehrlich and Malinow, 2004; McCormack
et al., 2006). In this scenario, scaffolding proteins are thought
to serve as placeholders or slot proteins for receptors such as
AMPARs. PSD-95 has been proposed to possess many quali-
ties of a slot protein (Schnell et al., 2002) because it is more
stable than other post-synaptic density (PSD) proteins such as
CaMKIIα, CaMKIIβ, GluR2 or Stargazin, consistent with a role
in regulating the PSD (Sturgill et al., 2009). Levels of PSD-
95 were reported to be redistributed to dendrites in the visual
cortex following eye opening in litters of rodents, and these
changes lasted upwards of 6 h and were contingent on sustained
environmental experience (Yoshii et al., 2003). Moreover, changes
in the sizes of individual PSDs over days were associated with
changes in PSD-95 retention times and PSD-95 increased with
developmental age and dropped sharply following sensory depri-
vation (Gray et al., 2006). Importantly, in FXS, there is evidence
that PSD-95 is dysregulated. Specifically, increased translational
levels were observed during basal states in Fmr1 KO as com-
pared to wild-type mice as well as relatively low protein levels
following stimulus induction in this genotype. PSD-95 mRNA
transcripts were also found to selectively deteriorate in the hip-
pocampus but not in the cortex or cerebellum of Fmr1 KO
mice (Todd et al., 2003; Muddashetty et al., 2007; Zhu et al.,
2011).
Pharmacological treatments blocking mGluR-5 receptors can
stabilize basal protein translation levels and this approach has
been hypothesized as a means of ameliorating some of the core
symptoms of FXS, including disorders in intellectual development
(Dölen and Bear, 2005; Bhakar et al., 2012). In studies using
drosophila KO (dfmr1) and Fmr1 KO murine models, the use
of mGluR-5 antagonists has been successful in correcting many
features of FXS including elevated and inappropriately expressed
protein levels at basal states, decreasing frequency of audiogenic
seizures, reversing excessive AMPA internalization, reducing the
number of abnormally thin dendritic spines, and reversing behav-
ioral/learning deficits (McBride et al., 2005; Yan et al., 2005;
Nakamoto et al., 2007; de Vrij et al., 2008; Pan et al., 2008; Choi
et al., 2010; Osterweil et al., 2010; Levenga et al., 2011; Su et al.,
2011; Tauber et al., 2011). Despite the rescue of many phenotypic
features of FXS, the identification of the specific proteins under-
lying these functions remains to be elucidated. Theoretically, the
stabilization of PSD-95 protein in Fmr1 KO mice would allow
for improved local regulation during periods of synaptic plasticity
while learning the H-W mazes.
Our Western blot analyses following completion of the H-W
mazes revealed that MPEP treated mice had statistically higher
PSD-95 protein levels. This effect was specific to PSD-95 since
levels of the control protein (β-tubulin) remained unchanged
across treatment conditions. Thus, our findings suggests that
PSD-95 protein deficits can be rescued by targeting mGluR-
5 receptors. An additional implication pertains to the broader
question of “when” it is appropriate to intervene with pharma-
cological treatment. As FXS is a developmental disorder, the vast
majority of animal model studies have targeted intervention at
the embryonic stages or very early in post-natal life. Concep-
tually, it is of great interest to determine if the FXS phenotype
Frontiers in Cellular Neuroscience www.frontiersin.org March 2014 | Volume 8 | Article 70 | 8
Gandhi et al. MPEP reverses deficits in Fmr1 KO mice
can be corrected after symptom onset. If not, it would suggest
that a critical therapeutic window has been missed and argue
against the idea that the symptoms of FXS are caused by ongoing
irregularities of synaptic signaling (Michalon et al., 2012). This
question was addressed in a study examining Fmr1 KO mice aged
4–5 weeks with anatomically developed and highly plastic brains,
corresponding to young adults. Specifically, treatment with an
mGluR-5 inhibitor corrected learning and memory deficits in an
inhibitory avoidance paradigm, improved dendritic spine abnor-
malities, and ameliorated elevated Extracellular signal-regulated
kinase (ERK) and mTOR kinase activation (pathways previously
shown to underlie the pathophysiology of FXS). Our data, which
suggest reversal of molecular and behavioral deficits, are consis-
tent with these findings (Michalon et al., 2012). In addition, since
the Fmr1 KO mice in our study were 12 weeks or older before
beginning behavioral testing, our findings further demonstrate
that a model of the FXS phenotype can be corrected in aged mice
roughly corresponding to adulthood.
The behavioral data from the H-W mazes were analyzed
according to two dependent variables of interest, latency and
error. Regarding the former, analyses of the treatment by maze
interaction indicated that there were differences in the latency
between MPEP and saline treated mice on several mazes. Owing
to high levels of variability in the runs times, faster completion
times by MPEP treated mice were not statistically different from
controls. However, the similar latency to complete mazes between
drug and vehicle groups indicates that our data are consistent with
previous research demonstrating that MPEP treatment does not
adversely affect locomotor activity (Yan et al., 2005; Silverman
et al., 2010; Mehta et al., 2011; Thomas et al., 2012). Collapsed
across treatment, we also observed that latency of maze com-
pletion was longest for trial 1 and generalizing across mazes,
tended to decrease with increased repetition. Thus, both groups
of mice were capable of improving their latency performance with
increased exposure to the mazes.
Consistent with our hypothesis, on mazes deemed more chal-
lenging (#8, 9, 11, 12; Shore et al., 2001), MPEP treated mice
made significantly fewer errors (i.e., #8, 11, 12). When examining
the behavioral performance of the mazes deemed more difficult,
on maze #8, saline treated mice continued to explore previously
unsuccessful routes towards the goal box whereas MPEP treated
mice demonstrated a reduction in errors over trials. Counterintu-
itively, there were no differences between drug and saline treated
mice on maze #9, which may reflect the variability in the data
set or a lack of difficulty of this maze for this background strain.
Qualitatively, on mazes #11 and #12, saline treated controls com-
mitted more perseverative errors, circling isolated and removed
barriers from the goal box, thereby getting stuck in unsuccessful
“loops”. That MPEP treated mice did not commit such responses
suggests that MPEP treatment may correct perseveration, a com-
mon cognitive feature of FXS (Hooper et al., 2008).
Finally, the treatment by trial interaction data revealed that
MPEP treated mice made significantly fewer errors on trials #1,
2, 4, and 5 relative to controls. Given that the largest effect size
occurred on the first trial, this suggests that MPEP may also have
corrected impulsive responding, which is another feature that is
commonly observed in FXS (Hagerman, 2002).
The pharmacological efficacy of MPEP was confirmed with
a marble burying assay immediately following the test phase in
order to validate our findings. Marble burying, a repetitive behav-
ior, has been shown to be decreased following the administration
of Grp I mGluR antagonists (Spooren et al., 2000; Thomas et al.,
2012). In the present investigation, MPEP treated mice buried
significantly fewer marbles than controls after the completion
of all mazes (thus confirming drug efficacy), with the exception
of #5. It is unclear why fewer marbles relative to controls were
buried here, however as there were no error differences between
treatment groups for this maze; interpretation of our findings is
not affected by this result.
Overall, our correlational findings are inconclusive and merit
further investigation. Although we replicated a negative correla-
tion between PSD-95 levels and mean errors for the entire sample
of mice, as found in our previous study (Gandhi et al., 2014), we
did not demonstrate a statistically significant relationship within
the treatment groups. We suspect that larger sample sizes of mice
will provide the necessary power to allow us to characterize this
relationship appropriately.
Whether pharmacological studies of mGluR-5 antagonists in
mouse models of FXS will translate into effective treatments
for human patients remains to be determined. To date, only
two studies have been completed in patients affected by FXS. A
pilot study was conducted to determine pharmacokinetics and
side effects of a single dose trial of the mGluR-5 antagonist,
fenobam, to 12 male and female FXS patients (Berry-Kravis et al.,
2009). Pre/post outcome measures included prepulse inhibition
(PPI) and the continuous performance test (CPT) to assess
sensory gating, attention and inhibition. The results indicated
there were no adverse reactions to the fenobam administration
and PPI improved by at least 20% in half of the sample rela-
tive to baseline. By comparison, performance on the CPT did
not improve although this finding was attributable to ceiling
effects. The other study employing an mGluR-5 antagonist was
conducted using AFQ056 in 30 male FXS patients ranging in
age from 18–35 (Jacquemont et al., 2011). These researchers
initially did not find any improvement in behavioral symptoms
of FXS following treatment as assessed by the Aberrant Behavior
Checklist-Community Edition (ABC-C). However, a subset of the
patients who had the full Fmr1 promoter methylation and no
detectable Fmr1 mRNA improved significantly more on the ABC-
C and the Repetitive Behavior Scale following treatment com-
pared with placebo. Since those patients with partial promoter
methylation did not show behavioral improvement following
AFQ056 treatment, the authors posited that mGluR-5 antagonism
might be better suited for FXS patients with full methylation
at the Fmr1 promoter. mGluR-5 antagonists are not the only
receptor mechanism/molecular target under investigation. FXS
is a complex neurodevelopmental disorder and Fmrp regulates
signaling by other receptors as well. Therefore, antagonism of
Group I mGluR signaling is not likely to produce beneficial
therapeutic effects for every patient. Moreover, there are other
aspects of the FXS phenotype that are unrelated to mGluR
function. Other research has focused on other targets and agents
such as GABA-A and B receptors, ampakines, brain derived neu-
rotrophic factor (BDNF), aripiprazole, lithium and intracellular
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signaling pathways via phosphatase and kinase inhibitors. In
all likelihood, patients will display varied outcomes to different
targeted treatments based on interplay between genetics, intra-
cellular neuronal pathways, and synaptic function (Gross et al.,
2012).
FXS is the most common single gene disorder associated with
autism spectrum disorder (Hagerman et al., 2010) and there are
numerous commonalities between FXS and autistic spectrum
disorder. Similar to FXS, many autistic patients suffer from seizure
disorder and cognitive impairment (Canitano, 2007). There is also
delayed language acquisition and repetitive behaviors (Hagerman,
1996) and 25–47% of FXS patients have a diagnosis of autism
(Kaufmann et al., 2004; Hatton et al., 2006). Models of FXS are
potentially advantageous to autism because Fmrp controls the
translation of plasticity proteins implicated in autism such as neu-
roligins and SHANK proteins (Darnell et al., 2011). Moreover, low
levels of FMRP relative to controls have been reported in autism
spectrum disorder (Fatemi and Folsom, 2011). Using a Black
and Tan BRachyury TBR T+ Itpr3tf/J (BTBR) murine model of
autism, one study reported that MPEP treatment ameliorated
repetitive self-grooming behavior without significant sedating
side effects (Silverman et al., 2010). Likewise, in a valproic acid
(VPA) murine model of autism, MPEP reduced excessive self-
grooming as well as marble burying behavior (Mehta et al., 2011).
Although further study is needed, preliminarily, MPEP appears
to be a suitable pharmacological intervention for both FXS and
autistic disorder. Our findings indicate that MPEP treatment
can reverse PSD-95 protein deficits and errors on more compli-
cated H-W test mazes. Given the significant phenotypic overlap
between FXS and autism as well as the lack of a viable behavioral
assay to test symptoms improvement in the autism field, the use of
the H-W mazes with murine models of autism spectrum disorder
appears promising and warrants further investigation.
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